quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:57:44·1249d
INSIDERFiling
Aerie Pharmaceuticals Inc. logo

SEC Form 4: Mcgraw Benjamin F Iii returned $640,256 worth of shares to the company (41,984 units at $15.25), closing all direct ownership in the company to satisfy tax liability

AERI· Aerie Pharmaceuticals Inc.
Health Care
Original source

Companies

  • AERI
    Aerie Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Aug 29UpdateCitigroup$15.25
  • Aug 23UpdateNeedham-
  • Aug 23UpdateCantor Fitzgerald$15.25
  • Feb 25UpdateNeedham$14.00
  • Nov 5UpdateNeedham$22.00
  • Aug 5UpdateNeedham$24.00

Related

  • 13D/G1168d
    SEC Form SC 13G/A filed by Aerie Pharmaceuticals Inc. (Amendment)
  • SEC1239d
    SEC Form 15-12G filed by Aerie Pharmaceuticals Inc.
  • NEWS1245d
    Aerie Pharmaceuticals's Return On Capital Employed Overview
  • PR1249d
    Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company's Ophthalmic Pharmaceutical Business
  • INSIDER1249d
    SEC Form 4: Mchugh Julie returned $245,449 worth of shares to the company (16,095 units at $15.25), closing all direct ownership in the company to cover taxes
  • INSIDER1249d
    SEC Form 4: Mcdonnell Peter J returned $121,924 worth of shares to the company (7,995 units at $15.25), closing all direct ownership in the company (for withholding tax)
  • INSIDER1249d
    SEC Form 4: Kopczynski Casey C. returned $4,273,721 worth of shares to the company (280,244 units at $15.25), closing all direct ownership in the company (withholding tax)
  • INSIDER1249d
    SEC Form 4: Lang Peter Frederick returned $706,029 worth of shares to the company (46,297 units at $15.25), closing all direct ownership in the company (for withholding tax)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022